Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Launch of a First Generic Version of Revlimid\u00ae (lenalidomide capsules), in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces FDA Approval of APHEXDA\u2122 (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"BioLineRx"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Pricing of $23 Million Public Offering of Securities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Gamida Cell"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell\u2019s Allogeneic Cell Therapy Omisirge\u00ae (omidubicel-onlv) Receives FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Gamida Cell"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Inks Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK\u00ae in a Multi-Regional Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medison Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Medison Pharma"},{"orgOrder":0,"company":"Padagis","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Doxil\u00ae (Doxorubicin Liposome Injection)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Padagis"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              BioLineRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Aut...

              Details:

              APHEXDA (motixafortide) is a CXCR4 antagonist , which is investigated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

              Lead Product(s): Motixafortide,G-CSF

              Therapeutic Area: Oncology Product Name: Aphexda

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Gamida Cell

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

              Details:

              Gamida Cell intends to use the net proceeds to fund the commercialization activities to support the launch of Omisirge (omidubicel-onlv) and the continued clinical development of GDA-201.

              Lead Product(s): Omidubicel-onlv

              Therapeutic Area: Oncology Product Name: Omisirge

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Piper Sandler & Co.

              Deal Size: $23.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering April 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Gamida Cell

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

              Details:

              Omisirge (omidubicel-onlv) ,FDA approved, is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy,it is indicated for hematologic malignancies who are planned for umbilical cord blood transplantation.

              Lead Product(s): Omidubicel-onlv

              Therapeutic Area: Oncology Product Name: Omisirge

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medison Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

              Details:

              The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.

              Lead Product(s): Tebentafusp-tebn

              Therapeutic Area: Oncology Product Name: Kimmtrak

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Immunocore

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teva Pharmaceutical Industries

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

              Details:

              Revlimid (lenalidomide capsules), a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, is first generic version available in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

              Lead Product(s): Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Lenalidomide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Padagis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Doxil® (Doxorubicin Liposome Injection)

              Details:

              Doxil® Liposome Injection is an anthracycline topoisomerase inhibitor indicated for Ovarian Cancer, AIDS-related Kaposi's Sarcoma and Multiple Myeloma.

              Lead Product(s): Doxorubicin Hydrochloride

              Therapeutic Area: Oncology Product Name: Doxil

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ayana Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medison Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medison Pharma Inks Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® in a Multi-Regional Agreement

              Details:

              Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).

              Lead Product(s): Ripretinib

              Therapeutic Area: Oncology Product Name: Qinlock

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY